Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections [0.03%]
用于血液学和肿瘤科单位无症状和轻症医护人员的新型冠状病毒(SARS-CoV-2)抗体快速检测识别出未被诊断的感染
Paolo Corradini,Giorgia Gobbi,Filippo de Braud et al.
Paolo Corradini et al.
Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs? [0.03%]
细胞因子谱分析可作为预测MPN预后的新型互补工具吗？
Hans C Hasselbalch
Hans C Hasselbalch
Congenital and Acquired Chronic Neutropenias: Challenges, Perspectives and Implementation of the EuNet-INNOCHRON Action [0.03%]
先天性和获得性慢性中性粒细胞减少症：挑战、展望以及EuNet-INNOCHRON行动的实施
Helen A Papadaki,Irene Mavroudi,Antonio Almeida et al.
Helen A Papadaki et al.
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure [0.03%]
一项评价Nivolimumab联合苯达莫司汀(NB)治疗接受过Nivolimumab单药治疗失败的复发/难治性霍奇金淋巴瘤患者的Ib期研究
Kirill V Lepik,Natalia B Mikhailova,Elena V Kondakova et al.
Kirill V Lepik et al.
This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received ...
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma [0.03%]
苯达莫司汀利妥昔单抗联用坦西罗莫用于复发套细胞淋巴瘤及滤泡性淋巴瘤的I/II期临床试验最终结果
Georg Hess,Karola Wagner,Ulrich Keller et al.
Georg Hess et al.
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous...
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study [0.03%]
意大利多中心研究淋巴系统肿瘤患者西尼罗病毒感染的临床特点及转归
Andrea Visentin,Vincenzo Nasillo,Monia Marchetti et al.
Andrea Visentin et al.
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome [0.03%]
达雷妥尤单抗联合来那度胺和地塞米松治疗POEMS综合征
Maria Gavriatopoulou,Ioannis Ntanasis-Stathopoulos,Despina Fotiou et al.
Maria Gavriatopoulou et al.
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma [0.03%]
达雷木单抗单药治疗西班牙多发性骨髓瘤患者的疗效和安全性：一项早期访问治疗方案的结果
Adrián Alegre,Javier de la Rubia,Anna Sureda Balari et al.
Adrián Alegre et al.
Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided ea...
Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant [0.03%]
复发/难治性ETP-ALL患者使用维奈克拉和奈拉滨治疗成功并行异基因干细胞移植的病例报告
Ashley McEwan,Omali Pitiyarachchi,Nicholas Viiala
Ashley McEwan
Case Reports
HemaSphere. 2020 Jun 8;4(3):e379. DOI:10.1097/HS9.0000000000000379 2020
Melania Tesio
Melania Tesio